Format

Send to

Choose Destination
Diagnostics (Basel). 2018 Feb 27;8(1). pii: E18. doi: 10.3390/diagnostics8010018.

Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report.

Author information

1
Nuclear Medicine Department, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy. a.mangano@scf.gov.it.
2
Medical Physics Unit, "Policlinico Umberto I" University Hospital, 00161 Rome, Italy. m.pacilio@policlinicoumberto1.it.
3
Radiology, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy. p.ialongo@scf.gov.it.
4
Nuclear Medicine Department, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy. a.semprebene@scf.gov.it.
5
Nuclear Medicine Department, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy. g.ventroni@scf.gov.it.
6
Nuclear Medicine Department, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy. l.mango@scf.gov.it.

Abstract

Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with 223Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the 223Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations.

KEYWORDS:

223Ra-dichloride therapy; bone metastasis; bone scan; prostate cancer

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center